Clinical trial · Interventional
Herbal Therapy in Treating Women With Metastatic Breast Cancer
A Pilot Safety, Feasibility, Efficacy And Correlative (Phase I/II) Study Assessing Herba Scutellaria Barbatae (HSB) For Metastatic Breast Cancer
NCT00028977CI-TRIAL-00008032completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: The Chinese herb Scutellaria barbata contains ingredients that may slow the growth of cancer cells and may be an effective treatment for metastatic breast cancer. PURPOSE: Phase I/II trial to study the effectiveness of Scutellaria barbata in treating women who have metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| herba scutellaria barbata | Drug | — | UNRESOLVED |
| herba scutellaria Barbatae (HSB) | Other | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed breast cancer (may include original primary cancer diagnosis) * Measurable disease * Metastatic involvement with minimal or no symptoms * Solitary metastases require histological confirmation * No extensive liver involvement (more than 50% of liver parenchyma) * No lymphangitic pulmonary involvement * CNS involvement or spinal cord compression allowed if stabilized by therapy for more than 3 months * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 18 and over Sex: * Female Menopausal status: * Not specified Performance status: * ECOG 0-1 Life expectancy: * More than 6 months Hematopoietic: * WBC at least 2,500/mm\^3 * Platelet count at least 75,000/mm\^3 Hepatic: * See Disease Characteristics * Bilirubin no greater than 1.7 mg/dL Renal: * Creatinine no greater than 2.0 mg/dL Other: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No history of multiple or severe food or medicine allergies PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 1 week since prior biologic therapy * No concurrent anticancer biologic therapy Chemotherapy: * At least 1 week since prior chemotherapy * No concurrent anticancer chemotherapy Endocrine therapy: * At least 1 week since prior hormonal therapy * No concurrent anticancer hormonal therapy Radiotherapy: * Not specified Surgery: * Not specified Other: * Recovered from prior anticancer therapy * At least 1 week since prior investigational agents * At least 1 week since prior herbal medications * No other concurrent anticancer therapy * No other concurrent investigational agents * Concurrent pamidronate allowed * Concurrent acupuncture or other nonherbal therapy allowed * Concurrent nutritional vitamin supplementation (up to 5 times recommended daily allowance) allowed
References
Publications (0)
Data not yet available
No reference posted for this study.